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www.cdatm.orgAbstractObjective: This study aims to determine the distribution of observed atherosclerotic cardiovascular disease (ASCVD) incidence in
contemporary cohorts in China, and to identify cut-off points for ASCVD risk classification based on traditional criteria and new
equations developed by Prediction for ASCVD Risk in China (China-PAR).
Methods: The study populations included cohorts in the China-PAR project, with 34,757 participants eligible for the current
analysis. Traditional risk stratification was assessed by using Chinese guidelines on prevention of CVD and hypertension, and 5 risk
groups were classified based on these guidelines after slight modification for available risk factors. KaplaneMeier analysis was
conducted to obtain the cumulative incidence of observed ASCVD events for all subjects and sub-groups. The predicted 10-year
ASCVD risk was obtained using the China-PAR equations.
Results: A total of 1922 ASCVD events were identified during an average follow-up of 14.1 years. According to the group
classification based on traditional risk stratification, the observed 10-year risks for ASCVD were 4.61% (95% confidence interval* Corresponding author. Fax: þ86 10 88363812.
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103X.-L. Yang et al. / Chronic Diseases and Translational Medicine 2 (2016) 102e109[CI]: 4.11e5.10%) in the moderate-risk group and 8.74% (95% CI: 7.82e9.66%) in the high-risk group. Based on the China-PAR
equations for risk assessment of ASCVD, those with predicted risks of <5%, 5e10%, and10% could be classified into categories
of low-, moderate-, and high-risk for ASCVD, respectively.
Conclusion: The findings enable development of a simple method for classification of individuals into low-, moderate-, and high-
risk groups, based on the China-PAR equations. The method will be useful for self-management and prevention of ASCVD in
Chinese adults.
© 2016 Chinese Medical Association. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Atherosclerotic cardiovascular disease (ASCVD) is
the leading cause of mortality and disease burden in
China.1 From 1990 to 2010, stroke became the leading
cause of death in China, followed by ischemic heart
disease.2 The rapid increase in ASCVD is attributable
to the aging population, lifestyle changes, and high
prevalence of ASCVD risk factors such as hyperten-
sion, dyslipidemia, diabetes, and obesity.3e5
Risk factors for ASCVD were first identified by the
Framingham Heart Study,6e8 followed by extensive
research in China and other countries.9,10 Several tools
and equations for risk stratification, such as the Fra-
mingham general cardiovascular disease (CVD)
equations8 and the Pooled Cohort Equations (PCE),11
have been developed to help healthcare practitioners
identify individuals at high-risk of CVD. In China, Liu
et al and Wu et al also developed risk prediction tools
for coronary heart disease (CHD) and ischemic CVD,
respectively, over 10 years ago.12,13 However, risk
factor profiles in China have changed dramatically,
and new equations have recently been developed by
Prediction for ASCVD Risk in China (China-PAR) to
predict 10-year ASCVD risk; these have been derived
and validated using 4 contemporary Chinese cohorts,
based on traditional lifestyles, metabolic risk factors,
and several new indicators such as waist circumfer-
ence (WC), geographic region (Northern vs. South-
ern), urbanization (Urban vs. Rural), and family
history of ASCVD.14 To facilitate the use of China-
PAR equations for ASCVD risk assessment in pre-
vention and clinical practice in China, we examined
ASCVD incidence and differences in ASCVD risk
among diverse age groups, genders, and geographic
regions.
In addition, the Chinese Guideline on Prevention of
CVD was published in 2011 and recommended a scale
of risk stratification for CVD prevention by classifying5 groups as very-low-, low-, moderate-, high-, and
very-high-risk.15 This scale of risk stratification was
also one of the main references for Chinese guidelines
on prevention and control of hypertension and dysli-
pidemia in the evaluation of risk for CVD. However,
traditional risk stratification was somewhat compli-
cated, and was not commonly used by primary
healthcare practitioners, especially in defined com-
munities and rural areas. As an alternative, the newly
developed China-PAR equations can serve as a valu-
able tool for prediction of 10-year ASCVD risk in the
general Chinese population; for the equations to be
useful, we must identify cut-off points for ASCVD risk
classification, and make these more accessible for
physicians and the general populations. Availability
through Web App tools is also necessary.
Therefore, we aimed to identify the distribution of
observed ASCVD incidence in large-scale contempo-
rary cohorts in China, and to determine cut-off points
for 10-year ASCVD risk stratification based on the new
China-PAR equations and traditional risk stratification
criteria derived from the Chinese Guidelines on Pre-
vention of CVD and hypertension.
Methods
Study population
The study population was derived from cohorts in
the China-PAR project, including those in the Inter-
national Collaborative Study of Cardiovascular Dis-
ease in Asia (InterASIA) and China Multi-Center
Collaborative Study of Cardiovascular Epidemiology
(China MUCA-1998 and China MUCA-1992-1994).
Details of baseline and follow-up information for the
cohorts have been published elsewhere.14 Briefly, a
total of 41,412 participants were enrolled in the 3 co-
horts. After excluding participants lost to follow-up,
those with ASCVD at baseline, and those with
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pants were eligible for the current analysis.
In addition to the 3 cohorts, the Community Inter-
vention of Metabolic Syndrome in China & Chinese
Family Health Study (CIMIC) was used for the com-
parison of trends for proportions of participants in
different risk categories. The CIMIC was a large
community-based cohort that was established for study
from 2007 to 2008 and completed follow-up surveys
from 2012 to 2015. Data from 69,102 participants aged
35e74 years and free of ASCVD were included in the
study.
These preceding studies were all approved by the
Institutional Review Board at Fuwai Hospital in Bei-
jing. Written informed consent was obtained from each
participant before data collection.
Definition of traditional risk stratification
Traditional risk stratification was assessed by using
the Chinese Guideline on Prevention of CVD.15 Five
risk groups were classified based on the guideline after
slight modification for the risk factors that we
measured (shown in Table S1). These risk factors
included: (1) aging (age > 55 years in men and >65
years in women); (2) current smoking; (3) lipid dis-
order (total cholesterol [TC]  200 mg/dl, or low-
density lipoprotein cholesterol [LDL-C]  130 mg/
dl, or high-density lipoprotein cholesterol [HDL-
C] < 40 mg/dl, or triglyceride [TG]  150 mg/dl); (4)
100  fast plasma glucose < 126 mg/dl; (5) obesity
according to WC (90 cm in men and 85 cm in
women) or body mass index (BMI  28 kg/m2); and
(6) family history of ASCVD.
Additionally, risk stratification for hypertensive
patients was modified based on the Chinese Guideline
on Hypertension Management in Primary Health-care
Clinics 2014 (shown in Table S2).16 The risk factors
required for the risk stratification scale were the same
as those shown above.
Definition of ASCVD
ASCVD was defined as nonfatal acute myocardial
infarction (MI), or CHD death, or fatal or nonfatal
stroke. Acute MI was defined as an increase in
biochemical markers of myocardial necrosis, accom-
panied by either ischemic symptoms, pathological Q
waves, ST segment elevation or depression, or coronary
intervention.17 CHD death included all fatal events due
to MI or other coronary deaths. Fatal or nonfatal stroke
included cases with signs of hemorrhage or cerebralinfarction, with rapidly developing focal (or global)
disturbances in cerebral function and lasting more than
24 h without apparent nonvascular cause.
Statistical analysis
Means or corresponding percentages of baseline
characteristics were calculated. Person-years of follow-
up were calculated as the difference between the date
of baseline and the date of ASCVD occurrence, the
date of death, or the last follow-up interview, which-
ever occurred first.
KaplaneMeier analysis was used to obtain the
observed ASCVD event rate in the cohorts from the
China-PAR project. The predicted 10-year ASCVD
risk was obtained using the China-PAR equations for
the same cohort participants. The China-PAR equa-
tions for 10-year ASCVD risk prediction were devel-
oped from gender-specific Cox proportional hazards
models, and the variables in the equations included
age, treated or untreated systolic blood pressure (SBP),
total cholesterol (TC), HDL-C, current smoking (Yes/
No), diabetes (Yes/No), WC, geographic region
(Northern/Southern), urbanization (Urban/Rural), and
family history of ASCVD (Yes/No), as well as avail-
able interaction terms for age with risk factors that met
predefined statistical criteria.14
All analyses were conducted using the SAS statis-
tical package (version 9.2; SAS Institute, Inc., Cary,
North Carolina, USA) and R software (version 3.2.3.
https://www.r-project.org/).
Results
The baseline characteristics of the participants are
presented in Table 1 according to the stratification
based on the Chinese Guideline on Prevention of CVD.
There were 6018, 16,922, 7303, 3813, and 701 par-
ticipants in the very-low-, low-, moderate-, high-, and
very-high-risk cohorts, respectively. The ages, BMI,
WC, blood pressure, TC, LDL-C, TG, and glucose
increased from the very-low-risk to the high-risk
group. Other than SBP and diastolic blood pressure
(DBP), the metabolic characteristics of participants in
the very-high-risk group were similar to those in the
high-risk group. Most current smokers and diabetic
patients were in the high-risk group, with 53.50% and
19.91%, respectively.
During an average follow-up of 14.1 years, a total of
1922 ASCVD events were identified. As shown in
Table 2, the observed 10-year risk for ASCVD using
KaplaneMeier adjustment ranged from 1.63% to
Table 1
Baseline characteristics of 34,757 subjects in cohorts from the China-PAR project.
Risk groupsa Very low Low Moderate High Very high
Sample size, n 6018 16,922 7303 3813 701
Age, years 43.72 (6.57) 46.58 (7.96) 50.54 (8.86) 53.28 (9.45) 53.23 (8.63)
Male, n (%) 1066 (17.71) 8332 (49.24) 4121 (56.43) 2506 (65.72) 379 (54.07)
BMI, kg/m2 21.59 (2.41) 22.55 (3.14) 24.14 (3.68) 25.76 (3.90) 25.65 (4.26)
WC, cm 71.21 (6.45) 75.74 (8.32) 80.98 (9.96) 86.85 (10.31) 85.08 (11.17)
SBP, mmHg 112.33 (11.42) 116.27 (12.24) 132.68 (19.59) 142.71 (14.44) 184.24 (19.11)
DBP, mmHg 72.57 (8.09) 75.02 (8.39) 83.89 (11.40) 88.46 (9.42) 107.95 (12.36)
Current smoker, n (%) 0 (0.00) 6078 (35.92) 3120 (42.72) 2040 (53.50) 268 (38.23)
TC, mg/dl 162.78 (22.37) 182.16 (37.56) 192.05 (39.91) 202.79 (41.03) 198.47 (43.59)
LDL-C, mg/dl 91.28 (19.89) 109.51 (33.06) 116.41 (35.36) 123.80 (36.15) 122.44 (40.73)
HDL-C, mg/dl 56.00 (10.88) 52.03 (13.54) 49.60 (13.89) 46.83 (13.55) 49.51 (13.61)
TG, mg/dlb 80.90 (65.00, 102.95) 104.60 (77.70, 145.00) 125.20 (90.00, 177.60) 151.80 (106.60, 212.50) 135.80 (97.30, 188.00)
Fasting plasma glucose,
mg/dl
83.08 (10.60) 87.34 (12.58) 99.29 (32.63) 112.80 (41.81) 102.94 (34.66)
Diabetes, n (%) 0 (0.00) 0 (0.00) 637 (8.72) 759 (19.91) 88 (12.55)
Family history of
ASCVD, n (%)
0 (0.00) 2336 (13.80) 1587 (21.73) 1095 (28.72) 158 (22.54)
Data were presented as means with standard derivation or the number of participants with percentages.
ASCVD: atherosclerotic cardiovascular disease; China-PAR project: Prediction for ASCVDRisk in China project; BMI: bodymass index; TC: total
cholesterol; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TG: triglyceride.
a Risk groups based on Chinese Guideline on Prevention of CVD in 2011.
b TG, median with interquartile range.
Table 2
KaplaneMeier-adjusted 10-year ASCVD risk in 34,757 subjects in cohorts from the China-PAR project.
Risk groups KaplaneMeier adjusted 10-year risk of ASCVD, %
Men (95% CI) P-valuea Women (95% CI) P-valuea
Age, years <0.001 <0.001
35e44 1.63 (1.33, 1.93) 0.89 (0.68, 1.10)
45e54 3.98 (3.47, 4.49) 2.38 (2.00, 2.76)
55e64 8.39 (7.38, 9.40) 5.23 (4.46, 6.00)
65e74 13.22 (10.49.15.94) 10.65 (8.15, 13.16)
Area 0.05 0.42
Urban 4.18 (3.68, 4.67) 2.54 (2.16, 2.92)
Rural 4.03 (3.64, 4.41) 2.46 (2.18, 2.75)
Geographic region <0.001 <0.001
Northern 5.40 (4.89, 5.90) 3.64 (3.25, 4.04)
Southern 2.90 (2.54, 3.26) 1.43 (1.19, 1.67)
ASCVD: atherosclerotic cardiovascular disease; China-PAR project: Prediction for ASCVD Risk in China project.
a P-value, log-rank tests for 10-year risk of ASCVD across subgroups.
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We found that the risk of ASCVD was higher among
elderly and urban subgroups, and in northern regions of
China. Men were consistently more susceptible to
ASCVD than women, regardless of subgroup. In
addition, the proportions of individuals with moderate-,
high- and very-high-risk for ASCVD have been
increasing, when we compared the trends in different
risk categories (Table S3).
Furthermore, the distribution of 10-year ASCVD
risk after KaplaneMeier adjustment was described for
5 groups using traditional risk stratification, based onthe Chinese Guideline on Prevention of CVD, as
shown in Table 3. We found that the observed 10-year
risks for ASCVD among all subjects were 4.61% (95%
CI: 4.11e5.10%) in the moderate-risk group and
8.74% (95% CI: 7.82e9.66%) in the high-risk group.
Gender-specific analysis showed similar results and
good consistency for the 10-year risks for ASCVD in a
comparison of men and women. When analyses were
conducted among hypertensive patients based on risk
stratification from Chinese guideline on hypertension
management, the observed 10-year risks of ASCVD
after KaplaneMeier adjustment were 5.42% in the
Fig. 1. Incidence of ASCVD across different risk stratification
groups. The 3 solid lines show the incidence of ASCVD based on the
Chinese Guideline on Prevention of CVD, with the very low and low
group as the green line, the moderate group as the blue line, and the
high and very high group as the red line. The 3 dashed lines show the
incidence of ASCVD based on the cut-off points from the China-PAR
equations, with green, blue, and red dashed lines for <5%, 5e10%,
and 10%, respectively.
ASCVD: atherosclerotic cardiovascular disease. China-PAR project:
Prediction for ASCVD Risk in China project.
Table 3
Ten-year ASCVD risk after KaplaneMeier-adjustment across different groups for risk stratification.
Risk groups Sample size, n KaplaneMeier adjusted 10-year ASCVD risk, %
All (95% CI) Men (95% CI) Women (95% CI)
Very low 6018 0.61 (0.41, 0.81) 0.68 (0.18, 1.18) 0.60 (0.38, 0.82)
Low 16,922 1.63 (1.44, 1.82) 1.80 (1.51, 2.09) 1.46 (1.20, 1.72)
Moderate 7303 4.61 (4.11, 5.10) 4.65 (3.98, 5.31) 4.55 (3.81, 5.29)
High 3813 8.74 (7.82, 9.66) 9.14 (7.98, 10.30) 7.98 (6.47, 9.49)
Very high 701 23.29 (20.06, 26.51) 27.92 (23.25, 32.59) 17.88 (13.59, 22.18)
Total 34,757 3.25 (3.06, 3.44) 4.13 (3.82, 4.44) 2.49 (2.26, 2.72)
ASCVD: atherosclerotic cardiovascular disease.
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(Table S4).
We published gender-specific China-PAR equations
for use as a tool to estimate 10-year risks of ASCVD in
general populations. The gender-specific equations
included variables of age, treated or untreated SBP,
TC, HDL-C, current smoking, diabetes, WC,
geographic region (Northern/Southern), urbanization
(Urban/Rural), and family history of ASCVD, as well
as available interaction terms for age with risk factors
that met predefined statistical criteria. To facilitate risk
assessment by using the China-PAR equations, 5% and
10% were used as cut-off points for simplified risk
categories based on the KaplaneMeier-adjusted risk
for ASCVD. Thus, a total of 34,757 participants in the
cohorts were divided into 3 new risk categories of
<5%, 5e10%, and 10%, as predicted by the China-
PAR equations; the participants in these cohorts were
also reclassified into 3 risk groups (very low and low,
moderate, and high and very high) based on traditional
stratification criteria derived from the Chinese Guide-
line on Prevention of CVD. Fig. 1 shows that compared
with the high- and very-high-risk groups, the ASCVD
incidence increased more quickly among individuals
with predicted 10-year ASCVD risk of 10%, based
on our China-PAR equations. However, the trend in the
incidence of ASCVD among individuals with predicted
risk of 5e10% increased faster than for those in the
traditional moderate group. Our new classification cut-
off points of 5% and 10% enabled easier identification
of moderate- to high-risk individuals for primary pre-
vention of ASCVD, compared with the results using
traditional risk stratification criteria based on the Chi-
nese Guideline on Prevention of CVD.
In addition, we compared the observed ASCVD
event rates to the predicted rates using our China-PAR
equations for the 3 groups with <5%, 5e10%, and
10% risk in the cohorts from the China-PAR project
(Fig. 2). After gender-specific analysis, there were no
substantial differences between the observed andpredicted rates. For example, the observed ASCVD
event rates in men were 1.49%, 7.46%, and 16.52%
across the 3 categories, for which the corresponding
predicted risks were 2.07%, 7.03%, and 16.23%,
respectively. Similar results were shown for women.
This illustrated the good agreement between observa-
tion and prediction when participants were classified
using predicted risk categories of <5%, 5e10%, and
10%.
Discussion
The current study showed the distribution of
observed 10-year risk for ASCVD among 34,757
Chinese adults aged 35e74 years. The 10-year risk
Fig. 2. Ten-year KaplaneMeier observed and predicted ASCVD
event rates among 34,757 participants in the cohorts from the China-
PAR Project. The observed ASCVD rates after KaplaneMeier-
adjustment are shown as white bars, and the predicted ASCVD rates
using the China-PAR equations are shown as black bars.
ASCVD: atherosclerotic cardiovascular disease; China-PAR: Pre-
diction for ASCVD Risk in China.
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and in those living in urban areas and northern regions
in China. Furthermore, we compared the 10-year risk
for ASCVD across different risk categories based on
the Chinese Guideline on Prevention of CVD and the
predicted risk based on the China-PAR equations. We
propose that predicted 10-year risk of less than 5%,
between at least 5% and less than 10%, and 10% or
more can be used as cut-off points for low-, moderate-,
and high-risk categories. The 3 simplified categories
based on predicted ASCVD risk derived from the
China-PAR equations provides an additional option for
evaluation of 10-year ASCVD risk, and enables iden-
tification of high-risk individuals beyond the tradi-
tional stratification derived from the Chinese Guideline
on Prevention of CVD.
It is a major challenge to control the epidemic of
CAD, stroke, and other forms of ASCVD, as well as
the associated risk factors in China. According to the
data in Table S3, the proportions of individuals with
moderate-, high- and very-high-risk for ASCVD have
been increasing in recent decades, although the study
design and inclusion of participants from 4 cohorts
were not perfectly comparative. For example, high-
and very-high-risk groups accounted for 14.79% of
total participants in 1998e2000, while subjects in the
CIMIC cohort at baseline in 2007e2008 accounted for
18.15% in the high- and very-high-risk groups. In
addition, Table 2 shows that men and women aged 55
years or older had a 10-year ASCVD risk of over 5%.
Men living in northern regions had a higher risk of
ASCVD. The distribution of 10-year ASCVD risk
varied among different subgroups. Therefore, risk
prediction is critical for identification of high-riskindividuals and for primary prevention of ASCVD in
general populations.
We developed and validated the China-PAR equa-
tions for 10-year ASCVD risk prediction in 4
contemporary Chinese cohorts. Based on the incidence
risk of ASCVD across 5 groups of risk stratification
(Table 3), we proposed 3 simpler risk categories of
low-, moderate-, and high-risk, with cutoff points of
5% and 10%. Furthermore, we also examined the
observed 10-year risk for ASCVD among hypertensive
patients, for whom risk stratification was performed
according to the Chinese Guideline on Hypertension
Management in Primary Health-care Clinics 2014
(shown in Table S2). Although the ASCVD risks were
slightly higher in men than in women across the 3 risk
groups as shown in Table S4, the cut-off points of 5%
and 10% were also applicable for classification of
hypertensive individuals into low-, moderate-, and
high-risk groups.
Risk prediction and assessment are also important
for guidance in lifestyle modification and management
of ASCVD risk factors. For example, the estimated
absolute 10-year risk of ASCVD, using the PCE
released by the American College of Cardiology and
American Heart Association (ACC/AHA), recom-
mended initiation of statin therapy for primary pre-
vention of ASCVD in individuals aged 40e75 with
LDL-C 70e189 mg/dl without clinical ASCVD or
diabetes.18 They should be treated with moderate- to
high-intensity statin therapy if they have an estimated
10-year ASCVD risk 7.5%, based on strong evi-
dence from randomized clinical trials; however,
treatment with a moderate-intensity statin was
reasonable with an estimated 10-year ASCVD risk of
5e7.5%. As another example, the Systematic Coro-
nary Risk Estimation (SCORE) charts developed by
the European Society of Cardiology used age, sex,
smoking status, TC, and SBP to estimate 10-year risk
of a first CVD event, and were recommended for
estimation of risk and prevention of CVD in European
populations.19 Categories in Europe were defined as
low-risk with a SCORE <1%, moderate-risk with a
1%  SCORE <5%, high-risk with a 5%  SCORE
<10%, and very-high-risk with a SCORE 10%.
Based on our current population data and analyses, we
simplified 3 risk categories by cut-off points of <5%,
5e10%, and 10%. We suggested that low-risk in-
dividuals with risk of <5% should be offered lifestyle
advice to maintain their low-risk status, while
moderate-risk individuals with predicted risk of
5e10% qualify for intensive lifestyle changes and
drug treatment if necessary. For high-risk individuals
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in addition to lifestyle changes. Nevertheless, uncrit-
ical initiation of drug treatment for all individuals with
risk over the 10% threshold should be discouraged.
The risk classification derived from cut-off points of
the China-PAR equations provides easily-applied
evaluation criteria to assist in risk assessment, while
the predicted risk must be interpreted in light of the
clinician's knowledge and experience of overall risk
factors that might modify the calculated risk.
Several limitations should be addressed in the cur-
rent study. In the traditional risk stratification using the
Chinese guidelines for both CVD prevention and hy-
pertension management, organ damage was one of the
risk classification criteria, reflected by electrocardio-
graphic or echocardiographic left ventricular hyper-
trophy, carotid wall thickening or plaque, and chronic
kidney disease with estimated glomerular filtration rate
(eGFR) < 60 ml$min1$1.73 m2. Using our
population-based design of large-scale cohort studies,
it was not possible to access detailed clinical test data.
Thus, we used age, smoking, blood pressure and other
metabolic risk factors such as lipids and fasting
glucose from routine blood tests to define the 5 groups
of ASCVD risk, which was feasible and reasonable in
large-scale population screening or studies of risk
assessment. Furthermore, we had eGFR measurements
for 11,746 participants in the InterASIA cohort. The
results for ASCVD incidence and cut-off point analysis
did not change substantially after the traditional risk
stratification included eGFR <60 ml$min1$1.73 m2
(data not shown). Finally, the principles of risk esti-
mation and cut-off points derived from the China-PAR
equations reflect an attempt to make complex issues
simple and accessible, but their simplicity also makes
them vulnerable to criticism. The risk classification
determined by cut-off points is arbitrary and an easily-
applied alternative to ASCVD risk assessment beyond
traditional stratification based on the Chinese guide-
lines on CVD prevention and hypertension manage-
ment. The health gains from preventive efforts for
individuals with different risk levels will warrant
further investigation in clinical trials and longer
observational studies.
In conclusion, risk assessment is a fundamental
component of prevention and management for
ASCVD. After determining the distribution of
observed 10-year ASCVD risk across traditional risk
stratification categories based on the Chinese guide-
lines on prevention of CVD and hypertension in our
cohorts, we proposed a simplified and easily-applied
method for classification of individuals into low-,moderate-, and high-risk groups, with cut-off points of
<5%, 5e10%, and 10% predicted by the China-PAR
equations. More aggressive risk factor modification
should be required among individuals with predicted
high risk. The China-PAR equations are valuable for
identification of high-risk individuals, and can be
widely applied for self-assessment and primary pre-
vention of ASCVD risk among general populations, as
well as potentially used for secondary prevention of
CVD in clinical practice in China.
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